Dissecting the Role of IL-12 in Naive CD8+ T cell Activation by Dendritic Cells
剖析 IL-12 在树突状细胞激活幼稚 CD8 T 细胞中的作用
基本信息
- 批准号:7322072
- 负责人:
- 金额:$ 4.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdoptive TransferAffectAntigen-Presenting CellsAntigensBiological AssayCD80 geneCD8B1 geneCell CommunicationCellsDendritic CellsDevelopmentEffector CellExcisionExhibitsFrequenciesGoalsImmunityIn VitroInfectionInflammatory ResponseInterferon Type IIInterleukin-10Interleukin-12Knock-outListeriaListeria monocytogenesLymphocyte ActivationMeasuresMediatingMemoryModelingMolecularMonitorNumbersPopulationProcessProductionPublic HealthReceptor SignalingRegulationResearch Project GrantsRoleT-Cell ActivationT-LymphocyteTestingTimeTranslatingVideo MicroscopyWorkbasecytokinecytotoxicdayfunctional outcomesimprovedin vivointerleukin-12 receptorpathogenreceptorresearch studytherapeutic vaccinetherapy designtumorvaccine developmentvector vaccine
项目摘要
DESCRIPTION (provided by applicant): Advancements in the development of vaccine vectors and adjuvants has vastly improved the quality of public health in recent decades. Interleukin 12 (IL-12) is a cytokine that has been shown to possess potent adjuvant activity, thus this cytokine could improve treatments designed against a variety of intracellular pathogens as well as tumors. A complete understanding of how IL-12, and its antagonist interleukin 10, dictates cytotoxic lymphocyte activation (CTLs) remains to be determined. The goal of this research project is to determine the mechanisms by which interleukin 12 (IL-12) and interleukin 10 (IL-10) produced upon dendritic cell infection with the model pathogen, Listeria monocytogenes regulate naive CD8+ T cell (CTL) activation and the development of a protective population of memory cells. Our lab has demonstrated that the neutralization of IL-10 in culture augments naive CTL activation during priming, while the neutralization of IL-12 has the opposite effect. Thus, we hypothesize that the cytokines IL-12 and IL-10 regulate the interactions between naive CD8+ T cells and Listeria-infected dendritic cells during priming and this regulation dictates the number of effectors that acquire the ability to confer protective immunity. In order to test this hypothesis we propose the following Specific Aims: Specific Aim 1: To determine how the cytokines IL-12 and IL-10 generated upon listerial cytoplasmic entry in dendritic cells regulate effector function of naive T cells as measured by interferon gamma in vitro and the protective capacity of these cells in vivo. Specific Aim 2: To determine if IL-12 or IL-10 regulate the frequency and duration of interactions between naive CD8+ T cells and Listeria- infected dendritic cells in vitro. In order to address these questions naive CTLs will be exposed to Listeria infected wild-type, IL-12 knockout, or IL-10 knockout DCs in vitro. The affects of the removal of these cytokines will be analyzed by monitoring interferon gamma production, IL-12 receptor signaling and polarization, and in vivo protection assays against Listeria monocytogenes after the adoptive transfer of naive CTLs. In addition, the duration and frequency of interactions between CTLs and DCs when IL-12 or IL-10 is neutralized will be monitored via time lapse video microscopy and flow cytometric based conjugate assays. By completion of my thesis project, I will have elucidated how IL-12 and IL-10 dictate the functional outcome of CD8+ T cells on the molecular level. The findings generated through this work could be translated into the improvement of currently used vaccines and therapeutics against a variety of intracellular pathogens and tumors.
描述(由申请人提供):近几十年来,疫苗载体和佐剂开发的进步极大地改善了公共卫生质量。白细胞介素12(IL-12)是一种细胞因子,已被证明具有有效的佐剂活性,因此这种细胞因子可以改善针对各种细胞内病原体以及肿瘤设计的治疗。关于IL-12及其拮抗剂白细胞介素10如何决定细胞毒性淋巴细胞激活(CTL)的完整理解仍有待确定。本研究项目的目标是确定模型病原体单核细胞增生李斯特菌感染树突状细胞后产生白细胞介素12(IL-12)和白细胞介素10(IL-10)的机制,调节幼稚CD 8 + T细胞(CTL)的激活和保护性记忆细胞群的发育。我们的实验室已经证明,中和培养物中的IL-10在引发期间增强幼稚CTL活化,而中和IL-12具有相反的效果。因此,我们假设细胞因子IL-12和IL-10调节初始CD 8 + T细胞和李斯特菌感染的树突状细胞之间的相互作用,并且这种调节决定了获得赋予保护性免疫能力的效应物的数量。为了验证这一假设,我们提出了以下具体目标:具体目标1:确定李斯特菌细胞质进入树突状细胞后产生的细胞因子IL-12和IL-10如何调节初始T细胞的效应器功能(通过体外干扰素γ测量)和体内这些细胞的保护能力。具体目标二:确定IL-12或IL-10是否调节初始CD 8 + T细胞与李斯特菌感染的树突状细胞之间的体外相互作用的频率和持续时间。为了解决这些问题,将在体外将幼稚CTL暴露于李斯特菌感染的野生型、IL-12敲除或IL-10敲除DC。将通过监测干扰素γ产生、IL-12受体信号传导和极化以及在幼稚CTL过继转移后针对单核细胞增生李斯特菌的体内保护测定来分析去除这些细胞因子的影响。此外,当IL-12或IL-10被中和时,CTL和DC之间相互作用的持续时间和频率将通过延时视频显微镜和基于流式细胞术的缀合物测定来监测。通过完成我的论文项目,我将阐明IL-12和IL-10如何在分子水平上决定CD 8 + T细胞的功能结果。通过这项工作产生的发现可以转化为目前使用的针对各种细胞内病原体和肿瘤的疫苗和治疗方法的改进。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Curtis James Henry其他文献
<em>αGal9Ab Treatment As a Novel Therapy for Blood Cancer</em>
- DOI:
10.1182/blood-2023-189449 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Miyoung Lee;Curtis James Henry - 通讯作者:
Curtis James Henry
emαGal9Ab Treatment As a Novel Therapy for Blood Cancer/em
EmαGal9Ab 治疗作为一种新型血液癌症疗法
- DOI:
10.1182/blood-2023-189449 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:23.100
- 作者:
Miyoung Lee;Curtis James Henry - 通讯作者:
Curtis James Henry
Curtis James Henry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Curtis James Henry', 18)}}的其他基金
Dissecting the relationship between declining lymphoid progenitor fitness and agi
剖析淋巴祖细胞适应性下降与敏捷之间的关系
- 批准号:
8541771 - 财政年份:2012
- 资助金额:
$ 4.1万 - 项目类别:
Dissecting the relationship between declining lymphoid progenitor fitness and agi
剖析淋巴祖细胞适应性下降与敏捷之间的关系
- 批准号:
8918490 - 财政年份:2012
- 资助金额:
$ 4.1万 - 项目类别:
Dissecting the relationship between declining lymphoid progenitor fitness and agi
剖析淋巴祖细胞适应性下降与敏捷性之间的关系
- 批准号:
9430563 - 财政年份:2012
- 资助金额:
$ 4.1万 - 项目类别:
Dissecting the relationship between declining lymphoid progenitor fitness and agi
剖析淋巴祖细胞适应性下降与敏捷性之间的关系
- 批准号:
8716539 - 财政年份:2012
- 资助金额:
$ 4.1万 - 项目类别:
Dissecting the relationship between declining lymphoid progenitor fitness and agi
剖析淋巴祖细胞适应性下降与敏捷之间的关系
- 批准号:
8383296 - 财政年份:2012
- 资助金额:
$ 4.1万 - 项目类别:
Dissecting the Role of IL-12 in Naive CD8+ T cell Activation by Dendritic Cells
剖析 IL-12 在树突状细胞激活幼稚 CD8 T 细胞中的作用
- 批准号:
7492170 - 财政年份:2007
- 资助金额:
$ 4.1万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 4.1万 - 项目类别: